Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vertex Pharmaceuticals filings document the biotechnology company’s operating results, governance and product-development disclosures. Recent Form 8-K reports include quarterly and annual results releases, selected regulatory and pipeline events involving therapies such as povetacicept, and officer or director transition disclosures.
The company’s proxy materials cover board composition, director nominees, shareholder meeting matters, executive compensation and equity-award information. Vertex filings also provide formal records for disclosure topics tied to its approved medicines, clinical pipeline and governance structure as a Nasdaq-listed operating company.
Vertex Pharmaceuticals executive Charles F. Wagner Jr. reported a tax-related share disposal. On February 13, 2026, he transferred 4,565 shares of common stock at $487.76 per share as a tax-withholding disposition, meaning shares were surrendered to cover taxes rather than sold on the open market. After this transaction, he directly owned 43,715 Vertex shares.
Vertex Pharmaceuticals executive Ourania Tatsis reported two stock transactions involving company common shares. On February 13, 2026, she disposed of 3,804 shares in a tax-withholding transaction at $487.76 per share and completed an open-market sale of 1,500 shares at a weighted average price of $499.99 per share.
The open-market sale was made under a company-approved Rule 10b5-1 trading plan entered into on August 21, 2025. Following these transactions, she directly owned 46,132 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev, EVP Chief Patient & External Affairs Officer, disposed of 3,548 shares of common stock on February 13, 2026 at $487.76 per share in a tax-withholding disposition. After this, he directly held 65,393 shares, with additional indirect holdings of 9,301 shares in a trust and 882 shares in a 401(k).
Vertex Pharmaceuticals executive Duncan McKechnie reported a tax-related share disposition. On this Form 4, he disposed of 2,283 shares of Vertex common stock on February 13, 2026 at an indicated price of $487.76 per share to cover tax obligations. After this transaction, he directly owned 19,528 shares.
Vertex Pharmaceuticals CEO Reshma Kewalramani reported a Form 4 tax-withholding disposition of 13,041 shares of common stock at $487.76 per share. After this transaction, she directly owns 133,487 Vertex shares.
Vertex Pharmaceuticals executive Mark E. Bunnage reported a tax-related share disposition. On this Form 4, he disposed of 2,283 shares of common stock at a price of $487.76 per share in a transaction coded "F," which represents payment of a tax liability by delivering shares, not an open-market sale. After this transaction, he directly owns 10,631 shares of Vertex common stock.
Vertex Pharmaceuticals executive reports tax-withholding share disposition. EVP and CMO Carmen Bozic disposed of 3,804 shares of Vertex Pharmaceuticals common stock on a tax-withholding basis at $487.76 per share. After this tax-withholding disposition, she directly holds 38,053 shares of Vertex common stock.
Vertex Pharmaceuticals executive Jonathan Biller reported two stock transactions. On February 13, 2026, he disposed of 2,993 shares of common stock at $487.76 per share to cover tax obligations and sold 988 shares in an open-market trade at $499.00 per share. After these transactions, he directly owned 16,838 shares of Vertex common stock. The filing notes the sale was made under a company-approved Rule 10b5-1 trading plan entered into on February 24, 2025.
Vertex Pharmaceuticals director Sangeeta N. Bhatia reported an open-market sale of 266 shares of common stock at $500 per share. After this transaction, she directly owns 4,299 shares. The sale was made under a company-approved Rule 10b5-1 trading plan entered into on 05/27/2025.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported a tax-related share disposition. On February 13, 2026, he disposed of 1,903 shares of Vertex common stock at $487.76 per share as a tax-withholding disposition and now directly holds 20,143 shares of common stock.